Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28475028 | 0.84 | SLC29A1 (0.46) | ADORA3ADORA1LMNATP53ALOX15 | |
| SCHEMBL30705001 | 0.83 | RXFP1 (0.39) | ADORA3ADORA1LMNATP53ALOX15 | |
| SCHEMBL17627818 | 0.83 | RXFP1 (0.39) | ADORA3ADORA1LMNATP53ALOX15 | |
| SCHEMBL30042226 | 0.81 | PI4KA (0.39) | ADORA3ADORA1LMNATP53ALOX15 | |
| SCHEMBL2463541 | 0.81 | ADORA3 (0.50) | ADORA3ADORA1ADORA2ASLC29A1 | |
| SCHEMBL29435121 | 0.79 | TARS1 (0.38) | ADORA1LMNATP53ALOX15TSHR | |
| SCHEMBL16987222 | 0.79 | TARS1 (0.38) | ADORA1LMNATP53ALOX15TSHR | |
| SCHEMBL28564130 | 0.79 | TARS1 (0.38) | ADORA1LMNATP53ALOX15TSHR | |
| SCHEMBL29137662 | 0.78 | SLC29A1 (0.42) | ADORA3ADORA1ADORA2ASLC29A1 | |
| Trifluoroacetic Acid SCHEMBL27715158 | 0.76 | ADORA3 (0.45) | ADORA3ADORA1ADORA2ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117821458-A | CRISPR/CAS related methods and compositions for treating beta-hemoglobinopathies | 爱迪塔斯医药公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117802102-A | CRISPR/CAS related methods and compositions for treating beta-hemoglobinopathies | 爱迪塔斯医药公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117043340-A | Oligonucleotides | 哈德森医学研究所 | 2023-11-10 | — | — | CN | disclosed |
| CN-116334142-A | CRISPR/CAS related methods and compositions for improving transplantation | 爱迪塔斯医药公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-108026526-B | CRISPR/CAS related methods and compositions for improving transplantation | 爱迪塔斯医药公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-109312338-A | CRISPR/CAS related methods and compositions for treating herpes simplex virus | 爱迪塔斯医药公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109312340-A | CRISPR-CPF1 correlation technique, composition and component for immunotherapy for cancer | 爱迪塔斯医药公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109153994-A | CRISPR/CAS related methods and compositions for treating β -hemoglobinopathies | 爱迪塔斯医药公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-108138183-A | For CRISPR-CAS correlation techniques, composition and the component of immunotherapy for cancer | 爱迪塔斯医药公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-108026526-A | CRISPR/CAS related methods and compositions for improved transplantation | 爱迪塔斯医药公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-106459995-A | CRISPR-associated methods and compositions using dominant grnas | 爱迪塔斯医药有限公司 | 2017-02-22 | — | — | CN | disclosed |